Profluent Will Design Enzyme Therapies With BioMarin Using AI Models

What changed

Profluent, a frontier AI lab for biology, announced on 30 September 2026 a collaboration with BioMarin Pharmaceutical to design and optimize novel enzyme therapies for BioMarin pipeline. Under the agreement Profluent will apply its foundational AI models to generate candidate proteins, and BioMarin will screen results with the goal of advancing promising designs toward preclinical testing.

Profluent models draw on the Profluent Protein Atlas, described in the release as more than 115 billion unique protein sequences. BioMarin brings enzyme replacement therapy expertise across genetically defined conditions. Executives framed the deal as combining de novo protein design speed with BioMarin track record of advancing enzyme drugs through clinic.

Developing and optimizing therapeutic enzymes traditionally requires extensive protein engineering and screening cycles. The collaboration aims to compress exploration of activity and stability profiles before wet lab validation.

Why it matters

Large pharma is pairing named foundation model shops with internal therapeutic area teams instead of treating AI as a generic IT purchase. For R&D portfolio managers, enzyme replacement is a concrete modality where design failures are expensive and timelines are long, so measurable cycle time reduction has direct NPV impact.

The deal also signals continued appetite for external innovation in rare disease pipelines where BioMarin already holds credibility.

Who is affected

Biologics discovery leads evaluating foundation model vendors for enzyme programs.

BD teams structuring AI collaborations with retained screening and advancement rights.

Investors tracking Profluent partnership cadence after prior pharma tie ups.

What to do next

If you run enzyme or biologics discovery, benchmark your current design cycle against the stated generate then screen workflow and ask vendors for preclinical hit rate data from analogous collaborations before signing platform licenses.

What to watch

Whether BioMarin discloses a named program entering preclinical evaluation with Profluent designed enzymes in 2027. A public program link would validate the collaboration beyond press release intent.

Sources

1. Primary. Business Wire via BioSpace, Profluent Partners With BioMarin to Design Novel Medicines Using AI (30 September 2026). Agreement scope, atlas scale, and executive quotes.
2. Secondary. Profluent corporate site news listing (30 September 2026). Confirms collaboration announcement date and modality focus.